Novo Nordisk: A Pharmaceutical Giant

Novo Nordisk's rise is largely attributed to its popular drugs, Ozempic and Wegovy. These medications, used for treating diabetes and obesity, have driven significant revenue and market value for the company.

In 2023, Novo Nordisk achieved substantial financial growth. The company's revenue reached approximately $34.41 billion, marking a significant 34.95% increase from the previous year. Additionally, their net profit soared to around $12.5 billion, reflecting a notable 51% YoY growth​.

Novo Nordisk's success has been a major driver of economic growth in Denmark, preventing the country from falling into recession. The company's innovative treatments have not only improved health outcomes but also boosted economic performance.